Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0366220160510030200
Korean Journal of Hematology
2016 Volume.51 No. 3 p.200 ~ p.203
Changes in serum uric acid levels after allogeneic hematologic stem cell transplantation: A retrospective cohort study
Joo Sang-Hyun

Park Jin-Kyun
Lee Eun-Young Emily
Song Yeong-Wook
Yoon Sung-Soo
Abstract
Background: Since cell turnover in the hematopoietic system constitutes a major source of uric acid (UA) production, we investigated whether hematopoietic stem cell transplantation (HSCT) is associated with significant changes in serum UA levels in patients with hematological disorders.

Methods: Patients who underwent HSCT at our institution between 2001 and 2012 were retrospectively enrolled. Serum UA levels at 3 months before, 1 week before, and 3 months and 1 year after HSCT were examined.

Results: Complete clinical and laboratory information including data regarding UA levels was available for 93 patients. At baseline, the mean UA level was 4.9¡¾2.1 mg/dL, with an overall prevalence of hyperuricemia of 15% (defined as serum UA>6.8 mg/dL). Mean UA levels tended to be higher in patients with acute myeloid leukemia (4.8¡¾2.0 mg/dL) and non-Hodgkin lymphoma (5.1¡¾2.3 mg/dL) and lower in patients with aplastic anemia (mean, 4.2¡¾1.8 mg/dL). UA levels dropped during myeloablative conditioning, reaching a nadir on the day of HSCT (3.27¡¾1.4 mg/dL). Over the 3 months following HSCT, UA levels rose sharply (5.0¡¾2.1 mg/dL) and remained stable up to 1 year after HSCT (5.5¡¾1.6 mg/dL). UA levels in HSCT recipients at 12 months correlated with those of their respective graft donors (Pearson r=0.406, P=0.001).

Conclusion: HSCT is associated with significant changes in uric acid levels in patients with hematologic disorders.
KEYWORD
Uric acid, Hematopoietic stem cell transplantation, Bone marrow
FullTexts / Linksout information
   
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø